Biotrial run PhI study halted after patient declared brain dead

By Gareth Macdonald contact

- Last updated on GMT

Biotrial HQ - credit Google map
Biotrial HQ - credit Google map

Related tags: Clinical trial

A clinical trial being run by Biotrial has been suspended after six serious adverse events.

According to the French Government​ the Phase I study was being conducted by Biotrial in Rennes in the Northwest of the country.

The Government said​ the research was halted after six* serious adverse events occurred.

It also confirmed earlier reports that one subject is in a coma​ after the study and that he has has been declared brain dead -"est en état de mort cérébrale​." The most recent updates state this patient has been declared "clinically dead."

According to the statement all injured volunteers are being cared for at the Centre Hospitalier Universitaire de Rennes (ou CHU de Rennes). The health condition of four of the patients is being described as "disturbing​."

AFP reported that the drug being trialed is a cannabis-based pain medication being developed by Portuguese pharmaceutical company Bial​. However, according to a BBC report​, this has been denied by the French health ministry.

Bial did not respond to a request for comment.

Biotrial told this publication it will stream a press conference on its website​ at 14h30 CET.

A statement on the French contract research organisation's (CRO)  website and Twitter​ now reads:

"During a FIM study which was being conducted for a sponsor, serious adverse events related to the test drug  have occurred in some subjects at our CPU. The trial has been conducted in full compliance with the international regulations and Biotrial’s procedures were followed at every stage throughout the trial, in particular the emergency procedures for the transfer of subjects to the hospital.

"We are in close and regular contact with the Health Authorities and Ministry in France. The priority at Biotrial remains the safety of our subjects. We are very grateful for the support we have been receiving from our clients and partners today​."

*French authorities have since confirmed that one of the five men showed no symptoms and was hospitalised as a precaution.

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars